BioPharm International - September 2023

BioPharm International - September 2023

Issue link: https://www.e-digitaleditions.com/i/1507932

Contents of this Issue

Navigation

Page 22 of 30

www.biopharminternational.com Emerging Therapies eBook September 2023 BioPharm International ® 23 Vaccines resources needed for manual processes, and the time taken to produce single therapies. Funding for these trials can be a limiting factor in mRNA cancer vaccine clinical development, particularly in the current global economic environment. Economic pressure is most im- pactful for emerging biopharma/biotechnology com- panies but impacts large pharmaceuticals as well. As the potential of mRNA vaccines for cancer be- comes increasingly clear, mRNA vaccine clinical development has seen an inf lux of f unding f rom government sources and investors. For example, the UK government announced a collaboration with BioNTech aimed at boosting research into cancer vac- cines (8). However, in the long run, making mRNA vaccines for cancer accessible to broader populations will require bringing down the cost of manufacturing single therapies. Conclusion While it is premature to say which evolving efforts in mRNA cancer vaccines will be most fruitful, all will benefit from accounting for key logistical con- siderations, including patient recr uitment, man- ufacturing, reg ulator y compliance, and f unding. Preliminar y successes of mRNA vaccines suggest they will soon be an invaluable tool in the immu- nology toolbox. References 1. Moderna and Merck Announce mRNA-4157/V940, a n Invest igat iona l Persona l ized m R NA Ca ncer Vaccine, in Combination With KEYTRUDA(R) (pem- brolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Com- plete Resection. Moderna. Accessed April 6, 2023. 2. Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pan- creat ic ca ncer. Nat ure. 2023;618(7963):14 4-150. doi:10.1038/s41586-023-06063-y 3. Barbier AJ, Jiang AY, Zhang P, Wooster R, Ander- son DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840- 854. doi:10.1038/s41587-022-01294-2 4. Ingels J, De Cock L , Mayer RL , et al. Small-Scale Manufacturing of Neoantigen-Encoding Messenger RNA for Early-Phase Clinical Trials. Cytotherapy. 2022;24(2):213-222. doi:10.1016/j.jcyt.2021.08.005 5. Ribas A. Adaptive Immune Resistance: How Can- cer Protects from Immune Attack. Cancer Discov. 2015;5(9):915-919. doi:10.1158/2159-8290.CD-15-0563 6. Mackensen A. BNT211-01: A Phase I Trial to Evalu- ate Safety and Efficacy of CLDN6 CAR T Cells and CLDN6-Encoding mRNA Vaccine-Mediated In Vivo Expansion in Patients with CLDN6-Positive Ad- vanced Solid Tumours. In: ; 2022. 7. Vuksanaj K. Next-Generation Cancer Vaccines Get Personal. GEN - Genetic Engineering and Biotech- nology News. Published August 9, 2022. Accessed June 22, 2023. 8. New Partnership to Boost Research into Vaccines for Cancer. GOV.UK. Accessed July 24, 2023. ■ Jeff Fischer co-founder and president, Longhorn Vaccines and Diagnostics Evaluating the Vaccine Marketplace Pharmaceutical Technology ® presents the Drug Solutions podcast, where the editors chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products. In this episode of the Drug Solutions podcast, one of the staff members of Pharmaceutical Technology ® speak with Jeff Fischer, co-founder and president of Longhorn Vaccines and Diagnostics, on the history and ongoing development of both protein- and mRNA-based vaccines. Topics of discussion include recent vaccine approvals, the broader state of the vaccine industry, and ideal use cases for both vaccine formulations. For more podcast episodes, visit PharmTech.com!

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - September 2023 - BioPharm International - September 2023